The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known ...

WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in ...

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...

Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...

Data presented at the American College of Cardiology’s 63rd Annual Scientific Session showed that evolocumab (Amgen) significantly reduced low-density lipoprotein (LDL) cholesterol as an add-on to ...

The US Food and Drug Administration (FDA) has approved evolocumab (Repatha, Amgen), a PCSK9 inhibitor, for use as add-on treatment to diet alone or with other therapies for children 10 years of age ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Amgen announced that the FDA has approved evolocumab as ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but ...